172 related articles for article (PubMed ID: 23787064)
41. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.
Robesova B; Bajerova M; Liskova K; Skrickova J; Tomiskova M; Pospisilova S; Mayer J; Dvorakova D
Lung Cancer; 2014 Jul; 85(1):25-30. PubMed ID: 24792336
[TBL] [Abstract][Full Text] [Related]
42. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.
Guo F; Liu X; Qing Q; Sang Y; Feng C; Li X; Jiang L; Su P; Wang Y
Biochem Biophys Res Commun; 2015 Apr; 459(3):398-404. PubMed ID: 25735977
[TBL] [Abstract][Full Text] [Related]
43. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
[TBL] [Abstract][Full Text] [Related]
44. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
45. [Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].
Zeng Z; Wu Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):880-4. PubMed ID: 22104224
[TBL] [Abstract][Full Text] [Related]
46. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.
Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433
[TBL] [Abstract][Full Text] [Related]
47. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.
Wang Y; Wang S; Xu S; Qu J; Liu B
PLoS One; 2014; 9(10):e110617. PubMed ID: 25360721
[TBL] [Abstract][Full Text] [Related]
49. Reliability Assurance of Detection of EML4-ALK Rearrangement in Non-Small Cell Lung Cancer: The Results of Proficiency Testing in China.
Li Y; Zhang R; Peng R; Ding J; Han Y; Wang G; Zhang K; Lin G; Li J
J Thorac Oncol; 2016 Jun; 11(6):924-9. PubMed ID: 26988569
[TBL] [Abstract][Full Text] [Related]
50. A novel KIF5B-ALK variant in nonsmall cell lung cancer.
Wong DW; Leung EL; Wong SK; Tin VP; Sihoe AD; Cheng LC; Au JS; Chung LP; Wong MP
Cancer; 2011 Jun; 117(12):2709-18. PubMed ID: 21656749
[TBL] [Abstract][Full Text] [Related]
51. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
[TBL] [Abstract][Full Text] [Related]
52. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
53. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
54. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Tanaka H; Hayashi A; Morimoto T; Taima K; Tanaka Y; Shimada M; Kurose A; Takanashi S; Okumura K
BMC Cancer; 2012 Nov; 12():558. PubMed ID: 23181703
[TBL] [Abstract][Full Text] [Related]
55. [A new target in non-small cell lung cancer: EML4-ALK fusion gene].
Wang H; Yuan J; Ma Z
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):538-42. PubMed ID: 21645460
[TBL] [Abstract][Full Text] [Related]
56. Small-cell transformation of
Balla A; Khan F; Hampel KJ; Aisner DL; Sidiropoulos N
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29317428
[TBL] [Abstract][Full Text] [Related]
57. Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.
Xiao D; Lu C; Zhu W; He Q; Li Y; Fu C; Zhou J; Liu S; Tao Y
Oncotarget; 2016 Sep; 7(37):59049-59057. PubMed ID: 27322143
[TBL] [Abstract][Full Text] [Related]
58. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
Murakami S; Yokose T; Saito H; Sakuma Y; Matsukuma S; Hasegawa C; Kondo T; Oshita F; Ito H; Tsuboi M; Nakayama H; Kameda Y; Noda K; Yamada K
Lung Cancer; 2010 Sep; 69(3):361-4. PubMed ID: 20659620
[TBL] [Abstract][Full Text] [Related]
59. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
60. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
Shinmura K; Kageyama S; Tao H; Bunai T; Suzuki M; Kamo T; Takamochi K; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
Lung Cancer; 2008 Aug; 61(2):163-9. PubMed ID: 18242762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
